Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes

NCT02556203 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02556203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02556203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Terminated
Start date
December 16, 2015
Completion date
November 27, 2018
Enrollment
1,653 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

transcatheter aortic valve replacement